Blood biomarkers are measurable molecules in blood that reflect physiological or pathological processes. Recent research shows they can help detect disease early, predict outcomes and guide treatment decisions across several conditions.

In traumatic brain injury (TBI), proteins released from damaged brain cells enter the bloodstream. Markers such as GFAP and UCH L1 are being used to assess injury severity and reduce unnecessary CT scans. Emerging work suggests blood tests could also help identify patients at risk of long term cognitive problems after TBI.

In multiple sclerosis, blood biomarkers aim to complement MRI. Neurofilament light chain, a marker of nerve fiber damage, is a leading candidate. Higher levels are associated with active inflammation, future relapses and brain atrophy, making it useful for monitoring treatment response and disease progression.

In stroke, biomarkers such as D dimer, inflammatory proteins and cardiac markers may help distinguish ischemic from hemorrhagic stroke, estimate infarct size and predict complications like hemorrhagic transformation. Combinations of biomarkers with clinical scores and imaging are being tested to refine diagnosis and prognosis.

The COVID 19 pandemic accelerated interest in blood biomarkers for infection and immune response. Patterns of inflammatory cytokines, coagulation markers and organ injury proteins can help stratify patients by risk of severe disease, respiratory failure or long term complications.

Across these fields, research is moving from single markers toward panels combined with clinical and imaging data, with the goal of more personalized and timely care. Challenges include standardization, validation in large diverse populations and ensuring tests are affordable and widely accessible.